m law group advises OrbiMed Advisors and Novo Nordisk in financing of Pieris AG
01.04.2008
m law group advises OrbiMed Advisors, LLC und Novo Nordisk
A/S in a EUR 25m series B financing of biotech company Pieris AG.
Pieris AG in Freising-Weihenstephan develops Anticalins®,
a novel class of protein therapeutics.
OrbiMed Advisors LLC, New York/USA is a major global fund
dedicated to the healthcare area.
Novo Nordisk A/S is a pharmaceutical company with
headquarters in Denmark and is a global leader in diabetes care.
The existing investors in Pieris AG, including Global
Life Science Ventures, Gilde Healthcare Partners and Forbion Capital Partners
participate in the series B financing round.
Counsel to OrbiMed Advisors and Novo Nordisk:
m law group: Rainer Kreifels (corporate; lead), Dr. Florian Anselm (corporate), Henno Groell (IP), Dr. Stephan Appt, LL.M. (IP).
Bingham McCutchen, Boston: James P. Carrigan (US law).
Clark & Elbing LLC, Boston: Kristina Bieker-Brady
(IP; lead).
Counsel to Pieris AG:
Holme Roberts & Owen, Munich: Dr. Jörg Ritter (lead,
corporate), Dr. Stefan Heyder, Dr. Christian Schröder.
Counsel to BayTech Venture Capital:
P+P Pöllath + Partner,
Munich: Otto Haberstock.
Practice Area:
Start-up & Venture Capital
Industry:
Life Science & Biotech
